Brief background of the Gleevec case

Posted on March 10th, 2007 by admin

In 1997, Novartis AG filed a patent application in the Chennai ( Madras) Patent Controller’s office for the beta-crystalline of Imatinib Mesylate, brand name Glivec (Gleevec) on the ground that they invented the beta crystalline salt form (imatinib mesylate) of the free base, imatinib. In 2003, it was granted Exclusive Marketing Rights (EMR) [...]

No Comments »
Filed under: Article, Campaign, News

Novartis to continue Indian patent fight

Posted on March 10th, 2007 by admin

Medical Patent News , March 8, 2007
A court in Chennai, India, last month heard arguments in the case regarding Novartis claims to Gleevec Patents in India. Some HIV/AIDS advocacy groups are calling on Novartis to drop its legal challenge, saying that if the company wins the case it could restrict access to antiretroviral drugs for [...]

No Comments »
Filed under: Campaign, News

  • Boycott Novartis is a campaign undertaken by the DRUG ACTION FORUM, India against Novartis, a pharmaceutical company dedicated to establishing a patent protected market in India, by the removal of barriers to competition. We are against Novartis patents, one pertaining specifically to access to treatment for thousands of patients suffering from Chronic Myeloid Leukemia (CML) and the other to a broader issue of the cost of new medicines that may be provided Patent protection.

  • Boycott Novartis
    ↑ Subscribe to this feed